Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
2024-11-12 09:31 am Purchase | 2024-09-30 | 13G | Immunic, Inc. IMUX | Adage Capital Management L.P. | 5,594,406 6.210% | 5,594,406![]() (New Position) | Filing History |
2024-11-12 09:31 am Unchanged | 2024-09-30 | 13G | Molecular Templates, Inc. MTEM | Adage Capital Management L.P. | 0 0.000% | 0 (Unchanged) | Filing History |
2024-11-12 09:31 am Purchase | 2024-09-30 | 13G | Aligos Therapeutics, Inc. ALGS | Adage Capital Management L.P. | 218,813 7.120% | 218,813![]() (New Position) | Filing History |
2024-11-12 09:31 am Purchase | 2024-09-30 | 13G | KalVista Pharmaceuticals, Inc. KALV | Adage Capital Management L.P. | 1,419,792 3.290% | 1,419,792![]() (New Position) | Filing History |
2024-11-12 09:31 am Purchase | 2024-09-30 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Adage Capital Management L.P. | 2,597,736 7.860% | 2,597,736![]() (New Position) | Filing History |
2024-11-12 09:30 am Purchase | 2024-09-30 | 13G | UroGen Pharma Ltd. URGN | Adage Capital Management L.P. | 3,735,741 8.870% | 3,735,741![]() (New Position) | Filing History |
2024-11-12 09:30 am Purchase | 2024-09-30 | 13G | Solid Biosciences Inc. SLDB | Adage Capital Management L.P. | 1,754,159 4.550% | 1,754,159![]() (New Position) | Filing History |
2024-11-12 09:30 am Purchase | 2024-09-30 | 13G | enGene Holdings Inc. Common Stock ENGN | Adage Capital Management L.P. | 2,329,768 5.270% | 2,329,768![]() (New Position) | Filing History |
2024-11-04 4:26 pm Purchase | 2024-10-29 | 13D | GlycoMimetics, Inc. GLYC | Adage Capital Management L.P. | 5,091,231 7.900% | 5,091,231![]() (New Position) | Filing History |
2024-10-22 4:15 pm Purchase | 2024-10-22 | 13D | Oruka Therapeutics, Inc. ORKA | Adage Capital Management L.P. | 175,000 0.500% | 175,000![]() (New Position) | Filing History |
2024-06-03 4:30 pm Purchase | 2024-05-31 | 13G | Abeona Therapeutics Inc. ABEO | Adage Capital Management L.P. | 4,210,429 9.990% | 4,210,429![]() (New Position) | Filing History |
2024-05-01 5:08 pm Unchanged | 2024-04-30 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | Adage Capital Management L.P. | 5,156,299 9.900% | 0 (Unchanged) | Filing History |
2024-04-30 8:53 pm Purchase | 2024-04-30 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | Adage Capital Management L.P. | 5,156,299 10.350% | 5,156,299![]() (New Position) | Filing History |
2024-04-05 4:05 pm Purchase | 2024-04-03 | 13D | ARCA biopharma, Inc. ABIO | Adage Capital Management L.P. | 100,000 8.280% | 100,000![]() (New Position) | Filing History |